A Certificate of Analysis — CoA — is the single document that stands between a buyer of a research peptide and total opacity about what is in the vial. In the FDA-regulated drug supply chain, CoAs are one artifact among many: they sit alongside lot release, GMP inspections, pharmacovigilance, and state-level pharmacy oversight. In the research-chemical market, the CoA is often the only artifact. That makes reading one carefully a basic literacy skill for anyone taking this space seriously.

A CoA is a batch-specific report from an analytical lab that answers, with varying degrees of rigor, four questions: what is the compound, how much of it is present, is it sterile, and is it free of endotoxin. Everything else — the seal, the header, the impressive-looking signature block — is packaging around those four numbers. A reader who can locate the four numbers and understand what generated them can evaluate a CoA in under a minute.

Batch-specific is not a suggestion

The most common failure mode in the research-peptide market is a 'CoA' that is generic — issued at some point in the past, for some unspecified lot, and reused across every subsequent shipment. A real CoA carries a lot or batch number that matches the physical label on the vial in the buyer's hand. If the number on the paper and the number on the vial do not match, the CoA is describing a different unit of product. It is, in effect, describing nothing.

The regulated pharmaceutical industry treats lot traceability as a non-negotiable primitive because manufacturing variability is real. Two lots produced weeks apart by the same facility can differ in impurity profile, moisture content, or residual solvent. The CoA exists to certify a specific lot; a report untied to a lot has surrendered the property it was created to establish.

Identity: mass spectrometry, not 'appearance'

Identity testing answers the question 'is this actually the molecule on the label?' The standard tool for peptides is mass spectrometry, most commonly LC-MS or MALDI-TOF, which measures the mass of the compound with enough precision to distinguish the target sequence from closely related analogs.^[1] A serious CoA will report the observed mass, the theoretical mass, and the delta between them; a professional report will also cite the ionization mode and the instrument used.

A report that describes identity by 'appearance,' 'physical description,' or 'organoleptic evaluation' is not answering the identity question. Peptides are typically white or off-white powders; that description is compatible with essentially any compound in the class and does not distinguish the labeled molecule from a substituted one. The absence of a mass spectrum on a peptide CoA is, on its own, disqualifying.

Potency: HPLC and the reference standard

Potency testing answers the question 'how much of the labeled molecule is actually here?' The standard tool is high-performance liquid chromatography (HPLC), often reported as reverse-phase HPLC (RP-HPLC), with UV detection.^[1] The technique separates the target compound from impurities on the basis of chemical affinity, and the peak area corresponding to the target is integrated against a reference standard of known concentration.

Two details separate a real potency figure from a decorative one. The first is the analytical method: a serious CoA cites the column, mobile phase, gradient, and detection wavelength, or at minimum a method reference number. The second is the reference standard: the potency value depends on comparing the sample against a known-pure standard of the same compound, and the sourcing of that standard is a legitimate line item on a report. A CoA that reports '99.4% purity' without describing how the number was arrived at is asking to be trusted, not read.

Sterility and endotoxin: the injectable questions

Because most research peptides are reconstituted and injected, two questions that do not apply to oral supplements become central. Sterility testing asks whether the product is free of viable microbial contamination; endotoxin testing asks whether it is free of the bacterial cell-wall fragments that survive sterilization and can provoke a systemic response even in a technically sterile product.^[2] Both are standard requirements for injectable pharmaceuticals and both are frequently absent from research-peptide CoAs.

A CoA that omits sterility, endotoxin, or both is silent on the specific category of risk that separates injectable products from everything else. It is not that the numbers are bad; the numbers do not exist. That is not the same class of information as a full report with defined acceptance criteria and a pass/fail against them.

Third-party versus in-house

A CoA generated by the seller's own quality lab and one generated by an independent, accredited third-party lab are structurally different documents. The in-house version has an obvious conflict-of-interest structure: the same organization that stands to lose revenue from a failing result decides whether to publish it. A third-party version — from a lab operating under ISO/IEC 17025 accreditation, with named contact information, a report number, and no financial relationship to the outcome — is a different order of evidence.

The most credible disclosures pair a named third-party lab with a lot number that a buyer can match to the physical product. Anything short of that traceability chain — a screenshot of a report with the header cropped, a PDF hosted on the seller's own domain and unlinkable to a specific unit — is a marketing artifact, not a quality artifact.

Spotting a decorative CoA

A short field checklist for the reader: Is there a batch or lot number, and does it match the vial? Is identity established by mass spectrometry with reported values? Is potency established by HPLC with a cited method? Are sterility and endotoxin present with pass/fail criteria? Is the lab named, contactable, and independent of the seller? A 'yes' on all five is the exception in the current market, not the norm. That gap between the paperwork buyers expect and the paperwork actually in circulation is the most honest description of where this industry sits in 2026.

Why this literacy matters

Even a perfect CoA does not answer whether a compound is safe or effective for a given use in a given person; it answers what is in the vial. That is a necessary but not sufficient precondition for every downstream question. Skipping it — trusting the label, trusting the brand, trusting the aesthetic of the PDF — is the failure mode this document is designed to prevent. Reading one carefully is not paranoia. It is the minimum diligence the category requires.